UPDATE 2-US FDA issues alert on kidney problems with Byetta - News

Runway Angels
The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Fashion Show.
The Richest Members of the US Congress
Recently, the Center for Responsive Politics found that there are 237 millionaires in the US Congress.
10 Tips to Get Out of Debt
Renowned financial author Gail Vaz-Oxlade takes a tough-love approach to helping couples in a financial crisis to face reality.

FEATURED QUIZZES

How Much Do You Know About Green?
Green has become part of our everyday lives. Green is everywhere-- energy, clothing, food, housing, transportation. It's a big business and a global business.
The Billionaire BFF's
Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?
The Many Myths of Coca-Cola
Can you tell which statements are true, and which ones are just rumors?

SPECIAL REPORTS

Winterizing Your Portfolio
If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.
Investor's Guide to Real Estate
Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.
Alternative Investing
Stocks and bonds? Sure. But it's a big world out there for investors.

CNBC ON DIGG

UPDATE 2-US FDA issues alert on kidney problems with Byetta

By: AFX | 02 Nov 2009 | 06:06 PM ET

Text Size

NEW YORK, Nov 2 (Reuters) - Patients and doctors should be aware of possible kidney function problems with Eli Lilly and Amylin Pharmaceuticals' Byetta diabetes drug, U.S. health regulators said on Monday. The U.S. Food and Drug Administration received 78 reports of problems with kidney function in patients using Byetta from April 2005 through October 2008. Nearly 7 million prescriptions for the drug were written during roughly the same period, so the agency noted the number of kidney problems represented a "small percentage" of the total number of patients on the drug. Nonetheless, the FDA approved changes to Byetta's prescribing label to include information about the kidney function reports. "Health care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," said Amy Egan, an FDA official in the agency's division of metabolism and endocrinology products. On Friday, Lilly and Amylin won approval to market the drug as a stand-alone treatment for type 2 diabetes. Byetta previously was approved only for patients who were taking other common diabetes medications and had not achieved adequate control of blood sugar. In a joint statement from the companies on Monday, Amylin Senior Vice President Orville Kolterman said post-approval reports of serious changes in kidney function "have been rare and usually complicated by other factors that could have contributed to the kidney problems." He added that there was "no evidence from preclinical and clinical studies that Byetta has any direct toxic effect on the kidney" and noted that diabetes itself is the leading cause of kidney failure. (Reporting by Lewis Krauskopf and Lisa Richwine; Editing by Tim Dobbyn and Carol Bishopric) Keywords: FDA/LILLY AMYLIN (lewis.krauskopf@thomsonreuters.com; 646-223-6082;Reuters Messaging:Lewis.Krauskopf.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Tools: